Melanoma: all 3,073 studies
Page 20 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.
- The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in GermanyWithdrawnNCT03205722
- Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United StatesCompletedNCT03199846
- Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma PatientsCompletedNCT03197636
- Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic MelanomaStatus unknownNCT03190824Phase 2
- Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App TechnologyWithdrawnNCT03177941Not applicable
- Evaluation of Pathway Modulation by Raf, MEK, & Kinase InhibitorsCompletedNCT03176485Not applicable
- Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain MetastasesActive, not recruitingNCT03175432Phase 2
- Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.CompletedNCT03174574
- Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal MelanomaCompletedNCT03172299Phase 3
- Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor TreatmentCompletedNCT03171064Phase 2
- Melanomas Excised in Primary Care vs Secondary Care ExcisionCompletedNCT03169036
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanCompletedNCT03165422
- Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has SpreadCompletedNCT03165409
- Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03161756Phase 1/2
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruitingNCT03161431Phase 1
- Pfizer PF-06688992 in Patients With Stage III or Stage IV MelanomaCompletedNCT03159117Phase 1
- The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) TrialCompletedNCT03158935Phase 1
- Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-oldCompletedNCT03155217
- A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaCompletedNCT03153085Phase 2
- A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])CompletedNCT03139513
- Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy EraStatus unknownNCT03138642Phase 2
- New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma TherapyCompletedNCT03136783Not applicable
- Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentStatus unknownNCT03132675Phase 2
- Early Therapy Response Monitoring in Melanoma Patients Using PET/MRIStatus unknownNCT03132090Not applicable
- Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedNCT03131908Phase 1/2
- SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2
- A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedNCT03114319Phase 1
- Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their PartnersCompletedNCT03112668Not applicable
- Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2
- Investigating the Clinical Utility of the MDSCompletedNCT03109327
- Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic MelanomaStatus unknownNCT03095079Phase 2
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownNCT03088176Phase 1
- Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and MelanomaStatus unknownNCT03086174Phase 1
- Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedNCT03084640Phase 1
- A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.CompletedNCT03073304Not applicable
- The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving ImmunotherapyCompletedNCT03073031Not applicable
- Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
- Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)TerminatedNCT03060356Early Phase 1
- Promoting Early Detection of Melanoma During the Mammography ExperienceCompletedNCT03057327Not applicable
- A Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsCompletedNCT03052205Phase 1
- A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1cStatus unknownNCT03048253
- Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 MelanomaCompletedNCT03034395Not applicable
- 18F-Labeled Picolinamide PET Imaging of Melanoma DiagnosisStatus unknownNCT03033485Not applicable
- Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaCompletedNCT03026517Phase 1
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1
- Vorinostat in Patients With Class 2 High Risk Uveal MelanomaWithdrawnNCT03022565Early Phase 1
- Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
- Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic MelanomaStatus unknownNCT03013101Phase 2
- High-activity Natural Killer Immunotherapy for Small Metastases of MelanomaCompletedNCT03007823Phase 1/2
- ML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWithdrawnNCT03005639Phase 2
- An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)CompletedNCT03002376Phase 1
- Fluorescence for Sentinel Lymph Node Identification in Cancer SurgeryCompletedNCT02997553Phase 3
- Melanoma Patients Immunized with Natural DenDritic CellsCompletedNCT02993315Phase 3
- Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyCompletedNCT02990611
- A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV MelanomaStatus unknownNCT02990416Phase 1/2
- MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersCompletedNCT02989064Phase 1
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruitingNCT02988960Phase 1
- SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical CarcinomaCompletedNCT02986867Not applicable
- Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaCompletedNCT02983006Phase 1
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
- Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous MelanomaTerminatedNCT02968680Phase 1
- Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
- MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma PatientsStatus unknownNCT02962947Phase 2/3
- Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma PatientsCompletedNCT02949154
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2
- Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced MelanomaStatus unknownNCT02938728
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyActive, not recruitingNCT02938299Phase 3
- Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver MetastasisCompletedNCT02936388Phase 2
- Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1
- IL2 Imaging in Metastatic MelanomaTerminatedNCT02922283Not applicable
- Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With MelanomaCompletedNCT02917473Not applicable
- A Clinical Trial of Patients With MelanomaWithdrawnNCT02915666Phase 1
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2
- Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
- Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic InfectionCompletedNCT02910557
- Immunophenotyping of Melanoma Patients on Treatment With PembrolizumabCompletedNCT02909348
- Circulating Tumor Material in Colorectal Cancer and MelanomaCompletedNCT02907086
- Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of BergamoCompletedNCT02902822Not applicable
- Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
- Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1
- Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncerCompletedNCT02893774Not applicable
- 18F-FLT PET Imaging in Patients With Advanced MelanomaTerminatedNCT02891616Phase 1
- Clinical and Histological Features of Head and Neck MelanomaCompletedNCT02883933
- Study of Risk Factors and Clinical Characterization of Rapidly Growing MelanomaStatus unknownNCT02879474
- Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)CompletedNCT02875652Not applicable
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsActive, not recruitingNCT02869217Phase 1
- Molecular Characterization of Advanced Stage Melanoma by Blood SamplingCompletedNCT02862743Not applicable
- Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible LesionsWithdrawnNCT02862145Phase 1/2
- Collaborative Network to Take Responsibility for Oral Anticancer TherapyStatus unknownNCT02861209Not applicable
- A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic MelanomaCompletedNCT02857569Phase 1/2
- Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node BiopsyCompletedNCT02857374Not applicable
- Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check PartnersCompletedNCT02854657Not applicable
- Yervoy Pregnancy Surveillance StudyWithdrawnNCT02854488
- Tracing Dissemination of Melanoma Cells in Healthy TissuesCompletedNCT02854124
- Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeCompletedNCT02847728